Hong Kong becomes ICH regulatory member, accelerating medical hub plan
Hong Kong has become the 20th regulatory member of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), three years after becoming an observer. The city plans to set up a drug and medical device regulatory centre next month.
Hong Kong has become a regulatory member of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), the Hong Kong government announced on 20 November 2026. The decision was taken at an ICH meeting in the Czech Republic on 17 November 2026, with the Hong Kong Pharmacy and Poisons Board representing the city as the 20th regulatory member. Other ICH regulatory members include China's National Medical Products Administration and regulators from Europe, Switzerland, Britain and the United States.
Professor Lo Chung-mau, Secretary for Health, said the government thanked the nation for supporting Hong Kong's development into an international medical innovation hub. He said Hong Kong's membership demonstrated the advantages of the 'one country, two systems' principle. Hong Kong became an ICH observer on 31 October 2023 and, with national support, met all requirements to become a full member within three years, far quicker than the eight to ten years the government had estimated based on international experience.
Lo added that the government would follow the First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (2026-2030) and support the national 15th Five-Year Plan by boosting biomedical clinical research and optimising review procedures for innovative and urgently needed medicines. The government will set up a Drug and Medical Device Regulatory Centre next month to build independent drug review capacity and participate in international cooperation.
Dr Lam Wai-keung, Director of Health, said joining the ICH was a key milestone for Hong Kong's drug review and regulatory reform, especially for the new centre. The centre will build an independent professional review team following ICH technical requirements, improve review efficiency for innovative drugs, and send experts to help draft and revise ICH guidelines. Hong Kong is already a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), having passed its audit in 2015 and become a full member on 1 January 2016.
The ICH coordinates global pharmaceutical registration technical requirements and sets international standards for safety, efficacy and quality to protect public health. The PIC/S leads international pharmaceutical development and implements strict good manufacturing practice guidelines and quality management systems for drug inspections.